{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:25:04Z","timestamp":1791347104168,"version":"4.3.1"},"reference-count":105,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"unspecified","delay-in-days":306,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Rev. Mol. Med."],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>Acute intermittent porphyria (AIP) is an autosomal dominant metabolic disease caused by hepatic deficiency of hydroxymethylbilane synthase (HMBS), the third enzyme of the heme synthesis pathway. The dominant clinical feature is acute neurovisceral attack associated with high production of potentially neurotoxic porphyrin precursors due to increased hepatic heme consumption. Current Standard of Care is based on a down-regulation of hepatic heme synthesis using heme therapy. Recurrent hyper-activation of the hepatic heme synthesis pathway affects about 5% of patients and can be associated with neurological and metabolic manifestations and long-term complications including chronic kidney disease and increased risk of hepatocellular carcinoma. Prophylactic heme infusion is an effective strategy in some of these patients, but it induces tolerance and its frequent application may be associated with thromboembolic disease and hepatic siderosis. Orthotopic liver transplantation is the only curative treatment in patients with recurrent acute attacks. Emerging therapies including replacement enzyme therapy or gene therapies (<jats:italic>HMBS<\/jats:italic>-gene transfer and <jats:italic>ALAS1<\/jats:italic>-gene expression inhibition) are being developed to improve quality of life, reduce the significant morbidity associated with current therapies and prevent late complications such as hepatocellular cancer or kidney failure in HMBS mutation carriers with long-standing high production of noxious heme precursors. Herein, we provide a critical digest of the recent literature on the topic and a summary of recently developed approaches to AIP treatment and their clinical implications.<\/jats:p>","DOI":"10.1017\/erm.2016.18","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T12:09:11Z","timestamp":1478088551000},"source":"Crossref","is-referenced-by-count":37,"title":["Emerging therapies for acute intermittent porphyria"],"prefix":"10.1017","volume":"18","author":[{"given":"Antonio","family":"Fontanellas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas A.","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"key":"S1462399416000181_ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.018"},{"key":"S1462399416000181_ref99","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024946216776"},{"key":"S1462399416000181_ref104","unstructured":"Sardh E. (2011) Insulin downregulates ALAS1 expression in human hepatocytes. Presented at the International Porphyrins and Porphyrias Meeting (10\u201314 April 2011; Cardiff, U.K.)"},{"key":"S1462399416000181_ref79","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.031"},{"key":"S1462399416000181_ref48","first-page":"213","article-title":"Special clinical, light and electron microscopic aspects of acute intermittent porphyria","volume":"8","author":"Heilmann","year":"1976","journal-title":"Annals of Clinical Research"},{"key":"S1462399416000181_ref84","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182"},{"key":"S1462399416000181_ref82","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-122"},{"key":"S1462399416000181_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(05)80072-6"},{"key":"S1462399416000181_ref43","first-page":"17","article-title":"Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria?","volume":"48","author":"Onuki","year":"2002","journal-title":"Cellular and Molecular Biology (Noisy-Le-Grand)"},{"key":"S1462399416000181_ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000703"},{"key":"S1462399416000181_ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032978"},{"key":"S1462399416000181_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90726-S"},{"key":"S1462399416000181_ref23","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22345"},{"key":"S1462399416000181_ref11","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.060772"},{"key":"S1462399416000181_ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.012"},{"key":"S1462399416000181_ref68","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.166"},{"key":"S1462399416000181_ref56","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3252"},{"key":"S1462399416000181_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/1011-1344(93)80127-U"},{"key":"S1462399416000181_ref40","volume-title":"Studies on Hepatic Disorders, Oxidative Stress in Applied Basic Research and Clinical Practice","author":"Urtasun","year":"2015"},{"key":"S1462399416000181_ref95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406228111"},{"key":"S1462399416000181_ref77","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0491"},{"key":"S1462399416000181_ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60140-9"},{"key":"S1462399416000181_ref66","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.210"},{"key":"S1462399416000181_ref27","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.97"},{"key":"S1462399416000181_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80097-5"},{"key":"S1462399416000181_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2014.06.012"},{"key":"S1462399416000181_ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607243150406"},{"key":"S1462399416000181_ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9576-9"},{"key":"S1462399416000181_ref16","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.12-3-293"},{"key":"S1462399416000181_ref93","unstructured":"NAPOS. The Drug Database for Acute Porphyria. In, http:\/\/www.drugs-porphyria.org [Accessed 5 August 2016]"},{"key":"S1462399416000181_ref2","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2014.891456"},{"key":"S1462399416000181_ref92","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3283193bc5"},{"key":"S1462399416000181_ref75","first-page":"A1","article-title":"Phase 1 clinical trial of liver directed gene therapy with rAAV5\/2-PBGD in acute intermittent porphyria: safety data","volume":"25","author":"D'Avola","year":"2014","journal-title":"Human Gene Therapy"},{"key":"S1462399416000181_ref62","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746040-00006"},{"key":"S1462399416000181_ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.05.009"},{"key":"S1462399416000181_ref37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.21847000.x"},{"key":"S1462399416000181_ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"S1462399416000181_ref96","unstructured":"Alnylam. Alnylam Pharmaceuticals. In http:\/\/www.businesswire.com\/news\/home\/20150915005532\/en\/ [Accessed 5 August 2016]"},{"key":"S1462399416000181_ref90","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122009764"},{"key":"S1462399416000181_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.06.036"},{"key":"S1462399416000181_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2014.08.014"},{"key":"S1462399416000181_ref61","doi-asserted-by":"publisher","DOI":"10.2119\/2004-00002.Johansson"},{"key":"S1462399416000181_ref58","doi-asserted-by":"publisher","DOI":"10.1042\/bst0180367"},{"key":"S1462399416000181_ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197307052890103"},{"key":"S1462399416000181_ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020090"},{"key":"S1462399416000181_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00990.x"},{"key":"S1462399416000181_ref17","doi-asserted-by":"crossref","unstructured":"Willandt B. (2015) Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD Rep","DOI":"10.1007\/8904_2015_458"},{"key":"S1462399416000181_ref97","doi-asserted-by":"publisher","DOI":"10.3727\/096368913X666980"},{"key":"S1462399416000181_ref87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401845101"},{"key":"S1462399416000181_ref73","unstructured":"AIPgene AIPgene Website. https:\/\/www.aipgene.org [Accessed 5 August 2016]"},{"key":"S1462399416000181_ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02358.x"},{"key":"S1462399416000181_ref67","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.64"},{"key":"S1462399416000181_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1988.tb13811.x"},{"key":"S1462399416000181_ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"S1462399416000181_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.05.005"},{"key":"S1462399416000181_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2014.11.001"},{"key":"S1462399416000181_ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000152455.38510.af"},{"key":"S1462399416000181_ref31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306627"},{"key":"S1462399416000181_ref25","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00099"},{"key":"S1462399416000181_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199201000-00001"},{"key":"S1462399416000181_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15646-8"},{"key":"S1462399416000181_ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2004.02.008"},{"key":"S1462399416000181_ref65","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.250"},{"key":"S1462399416000181_ref4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007139"},{"key":"S1462399416000181_ref80","doi-asserted-by":"publisher","DOI":"10.1089\/104303404322886138"},{"key":"S1462399416000181_ref86","unstructured":"youris Youris Website. http:\/\/www.youris.com\/Health\/Genetics\/Gene-Correction-For-A-Rare-Disease.kl [Accessed 5 August 2016]"},{"key":"S1462399416000181_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61925-5"},{"key":"S1462399416000181_ref89","doi-asserted-by":"publisher","DOI":"10.1136\/mp.51.2.96"},{"key":"S1462399416000181_ref94","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1288"},{"key":"S1462399416000181_ref78","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"S1462399416000181_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2004.09.030"},{"key":"S1462399416000181_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.03.032"},{"key":"S1462399416000181_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9544-4"},{"key":"S1462399416000181_ref91","doi-asserted-by":"publisher","DOI":"10.1177\/152692480901900315"},{"key":"S1462399416000181_ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.09.003"},{"key":"S1462399416000181_ref72","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2013.087"},{"key":"S1462399416000181_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.01035.x"},{"key":"S1462399416000181_ref7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.00189.x"},{"key":"S1462399416000181_ref98","unstructured":"Fogh J. and Andersson C. (2002) Process for purification of recombinant porphobilinogen deaminase. In International patent application number: PCT\/DK02\/00452"},{"key":"S1462399416000181_ref35","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200791"},{"key":"S1462399416000181_ref81","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3389"},{"key":"S1462399416000181_ref13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-6-200503150-00010"},{"key":"S1462399416000181_ref51","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26075"},{"key":"S1462399416000181_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390190115018"},{"key":"S1462399416000181_ref39","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i7.968"},{"key":"S1462399416000181_ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.12.022"},{"key":"S1462399416000181_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(86)90102-9"},{"key":"S1462399416000181_ref44","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(95)00015-P"},{"key":"S1462399416000181_ref55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2607"},{"key":"S1462399416000181_ref49","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1984.tb05005.x"},{"key":"S1462399416000181_ref83","doi-asserted-by":"publisher","DOI":"10.2174\/156652307782151425"},{"key":"S1462399416000181_ref64","unstructured":"Cardiff., T.H.G.M.D.a.t.I.o.M.G.i. http:\/\/www.hgmd.cf.ac.uk\/ac\/index.php. [Accessed 21 October 2015]."},{"key":"S1462399416000181_ref103","unstructured":"Wahlin S. (2011) Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Presented at the International Porphyrins and Porphyrias Meeting (10\u201314 April 2011; Cardiff, U.K.)"},{"key":"S1462399416000181_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.06.040"},{"key":"S1462399416000181_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70154-9"},{"key":"S1462399416000181_ref88","unstructured":"Fontanellas A. and Unzu C. (2015) Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases. In International patent application number: PCT\/EP2015\/070204"},{"key":"S1462399416000181_ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02335.x"},{"key":"S1462399416000181_ref36","first-page":"393","article-title":"Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations","volume":"5","author":"Bjersing","year":"1996","journal-title":"\u201cCancer Epidemiology, Biomarkers and Prevention\u201d"},{"key":"S1462399416000181_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2015_411"},{"key":"S1462399416000181_ref102","unstructured":"Fontanellas A. (2009) Porphobilinogen deaminase gene therapy. In International patent application number: PCT\/NL2009\/050584, Date of filing: 29.09.2009"},{"key":"S1462399416000181_ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.029"},{"key":"S1462399416000181_ref105","unstructured":"Bustad H.J. (2013) Searching for Pharmacological Chaperones Aiding to Stabilize Hydroxymethylbilane Synthase. Presented at the Annual Assembly SSCC\/Congress Porphyrins and porphyrias (May 16\u201318, 2013; Lucerne, Switzerland)"},{"key":"S1462399416000181_ref60","first-page":"CD010324","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"3","author":"Shemesh","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S1462399416000181_ref29","first-page":"66","article-title":"Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes","volume":"55","author":"Sardh","year":"2009","journal-title":"Cellular and Molecular Biology (Noisy-Le-Grand)"},{"key":"S1462399416000181_ref63","unstructured":"Andersson C. Randomized clinical trial of recombinant human porphobilinogen deaminase (rhPBGD) in acute attacks of porphyria. This study was presented as an oral presentation at the Porphyrins and Porphyrias International Meeting. Rotterdam, The Netherlands; April 29\u2013May 3, 2007. Session s06-5, page 45"}],"container-title":["Expert Reviews in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1462399416000181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T19:52:53Z","timestamp":1559937173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1462399416000181\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":105,"alternative-id":["S1462399416000181"],"URL":"https:\/\/doi.org\/10.1017\/erm.2016.18","relation":{},"ISSN":["1462-3994"],"issn-type":[{"value":"1462-3994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"e17"}}